Pfizer’s Abrysvo Is First Maternal Vaccine For RSV To Protect Infants
The vaccine, already approved for adults, was approved for pregnant women to protect infants from birth up to six months from complications caused by respiratory syncytial virus.
The vaccine, already approved for adults, was approved for pregnant women to protect infants from birth up to six months from complications caused by respiratory syncytial virus.